drugset / Trial / NCT01254227

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload

NCT01254227

Phase 2 Completed 60 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed be deferasirox monotherapy in patients with severe iron overload due to chronic blood transfusions.

Timeline

Start
2011-01
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 30.5 mg/kg
Subject Deferoxamine Other / unclassified 36.3 mg/kg

Indications